symbol,name,description,country,year,period,documentUrl,income,expenses,postedName,date,clientId,registrantId,senateId,houseRegistrantId
MNKD,MANNKIND CORPORATION,Glucose management for types 1 and 2 diabetes,US,2022,Q2,https://lda.senate.gov/filings/public/filing/5ead915e-c8f2-4276-8bdb-e1fbafae3d60/print/,30000,,,,210274,401105372,401105372-210274,401105372
MNKD,MANNKIND CORPORATION,Glucose management for types 1 and 2 diabetes,US,2022,Q3,https://lda.senate.gov/filings/public/filing/7fa4e29e-5b73-4f86-9a19-32d741596ac5/print/,30000,,,,210274,401105372,401105372-210274,401105372
